We scan new podcasts and send you the top 5 insights daily.
While multi-billion-euro funds are vital for later-stage European life sciences, their dominance absorbs available institutional capital and strains smaller fund raising. Sustaining a healthy innovation ecosystem requires democratizing institutional allocations rather than directing all capital to mega-funds.
Counterintuitively, raising a sub-$500 million fund is one of the most difficult tasks in today's market, regardless of whether it's a manager's first or fourth fund. The extreme supply-demand imbalance for capital and difficulty in differentiation means smaller funds struggle immensely to get allocators' attention.
To rival the US and China, a coalition of European VCs is focusing on three pillars: 1) simplifying and speeding up regulations, 2) attracting more institutional capital (e.g., pension funds) into life sciences, and 3) building a robust, NASDAQ-like public market to foster growth and retain wealth generation within Europe.
Kurma Partners' recent fundraise highlights a key challenge: while specialist and corporate investors eagerly back early-stage biotech, generalist institutional LPs are shifting away. These generalists now demand shorter hold times and favor funds investing in clinical-stage companies closer to an exit, creating a potential funding squeeze for preclinical innovation.
The huge funding gap for European biotech is structural. European institutional investors like pension funds allocate only 0.02% of their balance sheets to venture, compared to 2% in the US. This factor-of-100 difference creates a major hurdle for the ecosystem's ability to retain its champion companies.
High-performing European biotech VCs struggle to attract institutional capital not because of poor returns, but because the diligence on small funds is inefficient for large pension funds. They prefer writing larger checks to bigger funds, creating a structural barrier for smaller, specialized VCs to get funded.
LPs are concentrating capital into a few trusted mega-firms, leading to oversubscribed rounds for top players. Simultaneously, a decline in deal formation and liquidity is causing a potential 30-50% "extinction rate" for smaller, emerging managers who are unable to raise subsequent funds.
The venture capital landscape is bifurcating. Mega-funds attract the most capital and dominate large rounds, while specialized early-stage funds own the seed stage. This leaves traditional $200-400 million Series A funds in a precarious position, struggling to compete and facing difficulties raising their next funds.
Unlike their US counterparts, European biotechs have less access to large venture funds. This forces a culture of extreme capital efficiency and discipline. This need to be "cleverer, smarter with less people and less money" is a defining feature and potential advantage of the European ecosystem.
A tale of two venture markets is emerging. Large, established mega-funds are raising the bulk of capital and deploying it rapidly. Meanwhile, smaller, emerging managers face a tough environment, with the rate of firms successfully raising a second fund hitting a five-year low.
While overall venture capital investment in European biotech is rising, a critical gap remains at the earliest stage of company formation. According to the speaker, founders still find it very difficult to secure the initial "first capital" needed to get started, even as later-stage funding has grown tremendously in the region.